Prevalence, Pathophysiology, and Management of Androgen Deficiency in Men with Metabolic Syndrome, Type 2 Diabetes Mellitus, or Both.
The prevalence of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) has increased in the United States over the past 40 years. These conditions, long linked with many cardiovascular complications, have recently been linked with androgen or testosterone deficiency in men. Several pathophysiologic hypotheses exist regarding this association, with the most widely reported a relationship to obesity and insulin resistance. Several randomized trials have confirmed that when testosterone replacement therapy is given to patients with T2DM, MetS, or both, metabolic parameters such as waist circumference, hemoglobin A1c , and systolic blood pressure are significantly reduced by up to 11 cm, 1.9%, and 23 mm Hg, respectively. This has not, however, resulted in improved cardiovascular outcomes, as evidenced in studies that found increased rates of cardiovascular events following testosterone replacement therapy. In this review, we summarize the relevant literature regarding the pathophysiology and management of androgen deficiency in men with T2DM, MetS, or both.
Wingate University School of Pharmacy, Hendersonville, North Carolina.
Shawn Riser
SR
Taylor
Wingate University School of Pharmacy, Hendersonville, North Carolina.
Lindsy M
LM
Meadowcraft
Wingate University School of Pharmacy, Hendersonville, North Carolina.
Bobbie
B
Williamson
D000728:Androgens / Q000172:deficiency*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy*; D015995:Prevalence; D012306:Risk; D013739:Testosterone / Q000172:deficiency*
D000728:Androgens; D013739:Testosterone
androgen deficiency; hypogonadism; metabolic syndrome; testosterone deficiency; type 2 diabetes